Table 3.
Proportions of RCD in AD patients at the follow-up.
| With COVID-19 pandemic | Control | OR, 95%CI | |||
|---|---|---|---|---|---|
| Num. | RCD proportion (n, %) | Num. | RCD proportion (n, %) | ||
| Overall | 131 | 25 (19.1) | 131 | 48 (36.6)* | 0.408 (0.232–0.716)* |
| Initial CDR | |||||
| 1 | 49 | 9 (18.4) | 47 | 19 (40.4)* | 0.332 (0.131–0.839)* |
| 2 | 43 | 12 (27.9) | 47 | 16 (34.0) | ns |
| 3 | 39 | 4 (10.3) | 37 | 13 (35.1)* | 0.211 (0.061–0.726)* |
| ApoE genotypes | |||||
| ApoE ε4 (+) | 11 | 3 (27.3) | 19 | 8 (42.1) | ns |
| ApoE ε4 (–) | 30 | 7 (23.3) | 33 | 12 (36.4) | ns |
| Aβ deposition | |||||
| Positive | 39 | 9 (23.1) | 49 | 20 (40.8) | ns |
| Negative | 2 | 1 (50.0) | 3 | 0 (0.0) | ns |
| ApoE genotypes + Aβ deposition | |||||
| ApoE ε4 (+), Aβ (+) | 10 | 2 (20.0) | 19 | 8 (42.1) | ns |
| ApoE ε4 (+), Aβ (–) | 1 | 1 (100.0) | 0 | 0 (0.0) | ns |
| ApoE ε4 (-), Aβ (+) | 29 | 7 (24.1) | 30 | 12 (40.0) | ns |
| ApoE ε4 (-), Aβ (–) | 1 | 1 (100.0) | 3 | 0 (0.0) | ns |
In this study, only 55 patients, including 41 AD patients, in “during COVID-19 pandemic” group, and 52 patients with AD in control group had ApoE genotyping and Aβ deposition records. RCD, rapid cognitive decline; AD, Alzheimer's disease; Num., number of samples; OR, odds ratio; CI, confidence interval; CDR, Clinical Dementia Rate; ApoE, Apolipoprotein E; Aβ, Amyloid β.
*
p < 0.05.